Breaking Down SG&A Expenses: Perrigo Company plc vs Evotec SE

A Comparative Analysis of SG&A Expenses: Perrigo Company plc vs. Evotec SE

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Perrigo Company plc and Evotec SE from 2014 to 2023. Over this period, Perrigo consistently outpaced Evotec in SG&A spending, with an average annual expense of approximately $1.09 billion, compared to Evotec's $74 million. Notably, Perrigo's SG&A expenses peaked in 2023, reaching $1.27 billion, marking a 9% increase from 2014. Meanwhile, Evotec's expenses grew significantly, surging by 843% over the same period, reflecting its strategic expansion efforts. This financial trajectory highlights Perrigo's established market presence and Evotec's aggressive growth strategy. As the industry continues to evolve, these insights offer a glimpse into the operational priorities and strategic directions of these pharmaceutical giants.